DWS Capital Growth Fund
DEUTSCHE DWS INVESTMENT TRUST · 5 share classes
Fund classification
Classified from what the fund holds · as of 2026 Q2
DWS Capital Growth Fund is an actively managed U.S. equity fund. 44% of SDGAX’s stock holdings are in companies whose revenue grew in the top quartile of U.S. companies over the last five fiscal years (covering 94% of the fund’s equity).
- Asset class
- Equity
- Region
- United States
- Management
- Actively managed
- Fund type
- Open-end fund
- Features
- Non-diversified
Fund profile
As filed in the prospectus · 2026 Q1
The fund seeks to provide long-term growth of capital.
The fund employs a bottom-up stock selection process to identify large-cap U.S. growth companies it believes offer above-average and sustainable growth potential, using proprietary research and valuation metrics to guide security selection within risk parameters set by management. The fund normally invests at least 65% of assets in equities, mainly common stocks of companies similar in size to those in the S&P 500 Index or Russell 1000 Growth Index, though effective June 11, 2026, this will increase to at least 80% in growth companies as defined by the Russell 1000 Growth Index. Because portfolio performance depends on the quality of management's stock picks and their fundamental execution, returns may diverge materially from those of the indexes the fund references.
| Share class | Expense ratio |
|---|---|
| SDGAX | 0.89% |
| SDGCX | 1.76% |
| SCGSX | 0.66% |
| SDGTX | 0.69% |
| SDGZX | 0.59% |
Portfolio turnover 13.00% · as of 2026 Q1
Allocation
Asset groups · long / short shown separately, never netted · 2026 Q2
| Stocks | 98.53% |
| Cash & short-term | 2.95% |
Sector allocation
The same holdings as Allocation above, grouped by market sector instead of asset type · as of 2026 Q2
| Information Technology | 50.2% |
| Communication Services | 15.7% |
| Industrials | 12.3% |
| Health Care | 4.7% |
| 7 smaller | 17.1% |
Government, Securitized and Cash are non-corporate buckets; International is foreign holdings we don’t sector-classify, and Other is the residual (held funds, unresolved names).
Portfolio growth profile
How much of the fund’s stock holdings are in fast-growing companies · as of 2026 Q2
Share of the fund’s equity (by value) in companies whose trailing five-year revenue — or net-income — growth ranks in the top 25% of U.S. public companies. Foreign and newly-listed holdings are excluded, so the figure covers only part of the book. From SEC filings — not investment advice. How we measure this.
Latest quarter
What changed since the fund's previous filing
Return profile
Total return as filed — price change plus distributions reinvested · trailing figures to Apr 2026
| Share class | 1-year | 3-year | 5-year | Vol | Worst fall |
|---|---|---|---|---|---|
| +20.75% | +71.04% | +54.08% | 18.40% | -13.81% | |
| +19.71% | +66.68% | +47.61% | 18.39% | -14.13% | |
| — | — | — | — | — | |
| +21.04% | +72.31% | +55.91% | 18.41% | -13.73% | |
| +21.03% | +72.26% | +55.85% | 18.41% | -13.73% | |
| +21.10% | +72.58% | +56.41% | 18.41% | -13.71% |
May 2026 and Jun 2026 have been filed since the trailing figures were struck, so they are not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.
Holdings
By % of NAV · equity positions carry filed share counts · every resolvable issuer links to its company page
| Ticker | Issuer | %NAV | Reported price | Value | Shares |
|---|---|---|---|---|---|
| NVDA | NVIDIA CorpNVDA | 13.90% | $200.09 | $309.67M | 1.5M |
| AAPL | Apple IncAAPL | 6.86% | $289.36 | $152.91M | 528.4K |
| GOOGL | Alphabet IncGOOGL | 6.05% | $357.37 | $134.80M | 377.2K |
| AVGO | Broadcom IncAVGO | 5.27% | $377.75 | $117.41M | 310.8K |
| GOOG | Alphabet IncGOOG | 4.95% | $353.33 | $110.21M | 311.9K |
| MSFT | Microsoft CorpMSFT | 4.61% | $373.02 | $102.70M | 275.3K |
| AMAT | Applied Materials IncAMAT | 2.69% | $723.00 | $59.82M | 82.7K |
| META | Meta Platforms IncMETA | 2.42% | $563.29 | $53.99M | 95.8K |
| MRVL | Marvell Technology IncMRVL | 2.23% | $297.89 | $49.74M | 167.0K |
| LLY | Eli Lilly & CoLLY | 2.20% | $1,199.43 | $49.00M | 40.9K |
Reported price is the fund's own reported value divided by its own reported shares at 2026-06-30 — not a live quote, and not what the fund paid.
Top 10 positions are 51.18% of net assets, top 25 72.83%, across 71 issuers.
See more of this fund's book
More positions with filed share counts, and the quarter-over-quarter change list rather than the largest few — free with an account, no card required.
Sign in free